跳转至内容
Merck
CN

EHU051301

MISSION® esiRNA

targeting human WBP2

登录 查看组织和合同定价。

选择尺寸

关于此项目

NACRES:
NA.51
UNSPSC Code:
41105324

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

MISSION® esiRNA, targeting human WBP2

description

Powered by Eupheria Biotech

product line

MISSION®

form

lyophilized powder

esiRNA cDNA target sequence

CGTCAATAACACCGAGAGCATCCTAATGTCCTATGATCACGTGGAACTCACATTCAATGACATGAAGAACGTGCCAGAAGCCTTCAAAGGGACCAAGAAAGGCACTGTCTACCTTACCCCTTACCGGGTCATCTTTCTGTCCAAGGGCAAGGATGCCATGCAGTCCTTCATGATGCCATTTTATCTCATGAAAGACTGTGAGATCAAGCAGCCCGTATTTGGTGCAAACTACATCAAGGGAACAGTGAAGGCGGAAGCGGGAGGTGGCTGGGAAGGCTCTGCTTCCTACAAGTTGACTTTCACGGCAGGGGGCGCCATTGAGTTCGGACAGCGGATGCTCCAGGTGGCATCTCAAGCCTCCAGAGGTGAAGTCCCCAGTGGAGCCTATGGCTACTCTTACATGCCCAGCGGGGCCTATGTCTATCCCCCGCCAGTCGCCAATGGAATGTACC

Ensembl | human accession no.

ENSG00000132471

NCBI accession no.

NM_012478

shipped in

ambient

storage temp.

−20°C

Quality Level

100

Gene Information

human ... WBP2(23558), WBP2(23558)

General description

MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

存储类别

10 - Combustible liquids

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Shin-Ae Kang et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 25(8), 2588-2600 (2018-12-30)
Trastuzumab-based chemotherapy has shown remarkable clinical benefits for patients with HER2-positive breast cancer. However, treatment regimens involving trastuzumab had little or no effect for a subset of patients. Preliminary studies revealed WW-binding protein 2 (WBP2), an oncogenic transcription coactivator, to
Natania S Field et al.
European journal of immunology, 50(10), 1468-1483 (2020-05-28)
To mount an antipathogen response, CD4 T cells must undergo rapid cell proliferation; however, poorly controlled expansion can result in diseases such as autoimmunity. One important regulator of T-cell activity is the E3 ubiquitin ligase Itch. Itch deficient patients suffer

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持